PCRX VS AMRX Stock Comparison
Performance
PCRX10/100
10/100
PCRX returned -42.37% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
AMRX100/100
100/100
AMRX returned 95.22% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.
Analyst Price Targets
PCRX67/100
67/100
16 analysts offer 12-month price targets for PCRX. Together, they have an average target of 57.5, the most optimistic target put PCRX at 63 within 12-months and the most pessimistic has PCRX at 52.
AMRX
"Analyst Price Targets" not found for AMRX
Technicals
PCRX21/100
21/100
PCRX receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.
AMRX89/100
89/100
AMRX receives a 89 of 100 based on 14 indicators. 12 are bullish, 1 are bearish.
Earnings
PCRX10/100
10/100
PCRX has missed earnings 8 times in the last 20 quarters.
AMRX20/100
20/100
AMRX has missed earnings 5 times in the last 20 quarters.
Profit
PCRX55/100
55/100
Out of the last 20 quarters, PCRX has had 12 profitable quarters and has increased their profits year over year on 8 of them.
AMRX27/100
27/100
Out of the last 20 quarters, AMRX has had 5 profitable quarters and has increased their profits year over year on 4 of them.
Volatility
PCRX45/100
45/100
PCRX has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.
AMRX51/100
51/100
AMRX has had a higher than average amount of volatility over the last 12 months giving it a score of 51 of 100.
Sentiment
PCRX
"Sentiment" not found for PCRX
AMRX70/100
70/100
AMRX had a bullish sentiment score of 69.85% across Twitter and StockTwits over the last 12 months. It had an average of 3.50 posts, 0.50 comments, and 1.00 likes per day.
All score calculations are broken down here to help you make more informed investing decisions
Pacira BioSciences, Inc. Common Stock Summary
Nasdaq / PCRX
Healthcare
Drug Manufacturers - Specialty & Generic
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Amneal Pharmaceuticals, Inc. Class A Common Stock Summary
Nasdaq / AMRX
Healthcare
Drug Manufacturers - Specialty & Generic
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare PCRX to other companies in the same or a similar industry.